1. Brooks DJ, Frackowiak RSJ (1989) PET and movement disorders. J Neurol Neurosurg Psychiatry [Special Suppl]: 68–77
2. Eidelberg D, Moeller JR, Dhawan V, Sidtis JJ, Ginos JZ, Strother SC, Cedarbaum J, Greene P, Fahn S, Rottenberg DA (1990) The metabolic anatomy of Parkinson’s disease: complementary [18F] fluorodeoxyglucose and [18F] fluoro-dopa positron emission tomographic studies. Movement Disorders 5: 203–213
3. Hirato M, Kawashima Y, Shibazaki T, Shibasaki T, Ohye C (1989) Pathophysiology of parkinsonian rigidity (japanese). Functional Neurosurg 28: 1–9
4. Kuhl DE, Metter EJ, Reige WH (1984) Patterns of local cerebral glucose utilization determined in Parkinson’s disease by the [18F]Fluorodeoxyglucose method. Ann Neurol 15: 419–424
5. Leenders KL, Wolfson L, Gibbs JM, Wise RJS, Causon R, Jones T, Legg, NJ (1985) The effects of L-dopa on regional cerbral blood flow and oxygen metabolism in patients with parkinson’s disease. Brain 108: 171–191